BR112013029206B1 - composto, e, uso de um composto - Google Patents

composto, e, uso de um composto Download PDF

Info

Publication number
BR112013029206B1
BR112013029206B1 BR112013029206-7A BR112013029206A BR112013029206B1 BR 112013029206 B1 BR112013029206 B1 BR 112013029206B1 BR 112013029206 A BR112013029206 A BR 112013029206A BR 112013029206 B1 BR112013029206 B1 BR 112013029206B1
Authority
BR
Brazil
Prior art keywords
peptide
linker
psd
cpp
compound
Prior art date
Application number
BR112013029206-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013029206A2 (pt
Inventor
Anders Bach
Kristian Strømgaard
Original Assignee
Kobenhavns Universitet (University Of Copenhagen)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobenhavns Universitet (University Of Copenhagen) filed Critical Kobenhavns Universitet (University Of Copenhagen)
Publication of BR112013029206A2 publication Critical patent/BR112013029206A2/pt
Publication of BR112013029206B1 publication Critical patent/BR112013029206B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112013029206-7A 2011-05-13 2012-05-11 composto, e, uso de um composto BR112013029206B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485898P 2011-05-13 2011-05-13
US61/485898 2011-05-13
EP11165994 2011-05-13
EP11165994.2 2011-05-13
PCT/EP2012/058762 WO2012156308A1 (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Publications (2)

Publication Number Publication Date
BR112013029206A2 BR112013029206A2 (pt) 2017-02-14
BR112013029206B1 true BR112013029206B1 (pt) 2021-05-04

Family

ID=44367299

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029206-7A BR112013029206B1 (pt) 2011-05-13 2012-05-11 composto, e, uso de um composto

Country Status (13)

Country Link
EP (1) EP2707014B1 (https=)
JP (1) JP6084207B2 (https=)
KR (1) KR102046830B1 (https=)
CN (1) CN103533949B (https=)
AU (1) AU2012257774C1 (https=)
BR (1) BR112013029206B1 (https=)
CA (1) CA2833515C (https=)
DK (1) DK2707014T3 (https=)
ES (1) ES2544573T3 (https=)
IL (1) IL228893B (https=)
PL (1) PL2707014T3 (https=)
SG (1) SG194717A1 (https=)
WO (1) WO2012156308A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014356912B2 (en) 2013-12-01 2019-08-01 University Of Copenhagen Fatty acid derivatives of dimeric inhibitors of PSD-95
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CA3089161A1 (en) * 2018-02-02 2019-08-08 Kobenhavns Universitet Compounds for the treatment of acute brain injury
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN110787284A (zh) * 2019-11-23 2020-02-14 胡书群 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用
WO2021119756A1 (en) * 2019-12-20 2021-06-24 PYC Therapeutics Limited Novel cellular delivery methods
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
US20230346948A1 (en) * 2020-03-06 2023-11-02 University Of Copenhagen Lipid conjugated peptide inhibitors of PICK1
CA3203688A1 (en) * 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index
TW202306965A (zh) 2021-05-12 2023-02-16 哥本哈根大學 Ｐｓｄ－９５抑制劑及其用途
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN118027156B (zh) * 2023-09-07 2024-11-05 湖南中晟全肽生物科技股份有限公司 一种psd-95抑制剂及其用途
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
WO2025215348A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP2089052A4 (en) 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Also Published As

Publication number Publication date
BR112013029206A2 (pt) 2017-02-14
AU2012257774C1 (en) 2016-11-03
CA2833515A1 (en) 2012-11-22
SG194717A1 (en) 2013-12-30
EP2707014A1 (en) 2014-03-19
CA2833515C (en) 2017-11-28
EP2707014B1 (en) 2015-06-17
KR102046830B1 (ko) 2019-11-20
AU2012257774B2 (en) 2016-07-28
CN103533949A (zh) 2014-01-22
KR20140038435A (ko) 2014-03-28
IL228893B (en) 2018-01-31
IL228893A0 (en) 2013-12-31
JP2014514365A (ja) 2014-06-19
AU2012257774A1 (en) 2013-11-07
CN103533949B (zh) 2015-11-25
PL2707014T3 (pl) 2015-12-31
WO2012156308A1 (en) 2012-11-22
ES2544573T3 (es) 2015-09-01
DK2707014T3 (en) 2015-09-14
JP6084207B2 (ja) 2017-02-22

Similar Documents

Publication Publication Date Title
AU2012257774B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
US9458465B2 (en) Compositions and methods to modulate cell membrane resealing
JP6319738B2 (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
BRPI0721259B1 (pt) composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
ES2641325T3 (es) Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
BR122021025449B1 (pt) Composto, polipeptídeo e composição compreendendo o mesmo
US20100016242A1 (en) Myosin light chain kinase inhibitors and methods of use
JP2012236828A (ja) 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
BR112020017385A2 (pt) Análogos de compstatina, métodos e seus usos médicos
ES2644554T3 (es) Péptidos cíclicos con actividad antiangiogénica y antineoplásica
US7420030B2 (en) Aminopeptidase A (APA) targeting peptides for the treatment of cancer
EP2799445B1 (en) Integrin blocker polypeptide for use in the treatment of rheumatoid arthrits
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
JPH09501910A (ja) 血栓症処置のための方法および組成物
ES2541308T3 (es) Agonistas y antagonistas completos y parciales altamente potentes del receptor de nociceptina/orfanina FQ
ES3005857T3 (en) Novel peptoids and use thereof for preventing or treating chronic pain
BRPI0618994A2 (pt) tratamento de desordens neurodegenerativas
Davies Analogue and Conformational Studies on Peptides, Hormones and Other Biologically Active Peptides
BR112018012174B1 (pt) Composição farmacêutica que compreende um polipeptídeo inibidor de c5, kit, dispositivo de auto injetor e uso
BR112017012896B1 (pt) Uso de um polipeptídeo cíclico, composição farmacêutica e processo para produzir a composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2012, OBSERVADAS AS CONDICOES LEGAIS.